Eli Lilly upgrades earnings per share guidance
On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
US-based pharmaceutical company Eli Lilly has presented results from the third quarter of 2021, and in connection with the release, expectations for earnings per share have been adjusted.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
US court orders Eli Lilly to pay royalties on diabetes drugs
For subscribers
